Top Industry Leaders in the Bladder Cancer Market
Latest Bladder Cancer Companies Update:
CG Oncology: Their oncolytic virus therapy, cretostimogene grenadenorepvec, received both FDA Fast Track and Breakthrough Therapy designations for high-grade non-muscle invasive bladder cancer (NMIBC), potentially offering a novel treatment option with accelerated approval pathway.
AstraZeneca: Initiated Phase 3 trials for their PARP inhibitor, olaparib, in combination with standard chemotherapy for muscle-invasive bladder cancer, aiming to improve survival outcomes.
Bayer Collaborated with a research institution to develop novel antibacterial coatings for medical devices used in bladder cancer procedures, potentially reducing infection risks.
Roche Their TECENTRIQ® (atezolizumab) received US FDA approval for first-line treatment of locally advanced or metastatic urothelial carcinoma, expanding treatment options for bladder cancer patients.
Merck Announced a new manufacturing agreement for Bacillus Calmette-Guérin (BCG), a critical therapy for NMIBC, addressing the global shortage and ensuring patient access.
Medtronic Introduced their latest BlueTouch™ electrocautery system designed for improved precision and tissue preservation in robotic bladder cancer surgery.
Myovant Sciences Their GnRH antagonist, relugolix, is undergoing Phase 3 trials for non-surgical pain management in advanced bladder cancer, offering a potential alternative to invasive procedures.
List of Bladder Cancer Key companies in the market
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc.
- Novartis International AG
- Pfizer Inc.
- Sanofi S.A.
- Merck & Co. Inc.
- Accord Healthcare
- Bedford Lab